An addiction researcher shares 6 strategies to address the opioid epidemic

first_img 2 COMMENTS Previous articleJoin The Apopka Voice team: Sales Associate neededNext article12 Tips for Shopping at Goodwill Denise Connell RELATED ARTICLESMORE FROM AUTHOR Reply UF/IFAS in Apopka will temporarily house District staff; saves almost $400,000 Reply Irvin Waller, author of Smarter Crime Control which is guide to politicians based on evidence – see web and twitter Florida gas prices jump 12 cents; most expensive since 2014 Robert Jan Hedgepath, LCSW, LCAS Save my name, email, and website in this browser for the next time I comment. Please enter your name here Share on Facebook Tweet on Twittercenter_img April 28, 2018 at 3:01 pm May 4, 2018 at 10:59 am By Nabila El-Bassel, Professor of Social Work, Director of Social Intervention Group, Columbia University.Editor’s Note: This article first published on theconversation.comThe devastating opioid epidemic is one of the largest public health problems facing the U.S. Over 2.5 million people in the U.S. suffer from opioid use disorder.Four in five new heroin users started out misusing prescription painkillers. A 2015 analysis by the Centers for Disease Control and Prevention found people who are addicted to painkillers are 40 times more likely to be addicted to heroin.The epidemic actually began more than three decades ago. In 1980, crack and cocaine addiction contributed to the thousands of overdose deaths, whereas now people die from pain relievers and synthetic opioids such as fentanyl.In 1990, I began studying its relationship to HIV and the experiences of people with multiple addictions. My research team and I have recruited research participants from emergency rooms, methadone programs, jails, prisons, an alternative to incarceration projects, and HIV and primary care clinics. We have examined barriers to accessing care for drug addiction and HIV, and some of the lessons we have learned apply to the broader population.Two faces of the opioid addictionYears ago, I interviewed Jennifer, a former nurse, who was prescribed antidepressants to cope with childhood sexual abuse trauma. When this didn’t help, she stole narcotics from her clinic and was fired. With no access to pain pills, Jennifer began using heroin and cocaine. She reported facing stigma from health care providers due to her addiction, and she lacked access to counseling for depression. Jennifer’s case is not unique; many women face a lack of access to services addressing trauma and gender-based violence.Tarryn Vick takes a dose of methadone at a clinic in Hoquiam, Wash., where she is being treated for drug addiction, June 15, 2017. AP Photo/David GoldmanMore recently, our research team interviewed John, who started using narcotics prescribed for back pain. His need for increasingly higher dosages exceeded the number of pills his physician would prescribe, so he turned to friends and then began heroin and injection drug use.Although incarcerated numerous times for accidents while driving impaired, he said he was never asked about addiction or referred to drug treatment by his primary care office. Since John detoxed “cold turkey” in prison, he often overdosed after his release, reuniting with his “running buddies.” Recently, one of John’s buddies saved his life by using a free naloxone kit from a health department stall at a street fair. John was lucky: Thousands of opioid users cannot access naloxone.Not addressing the core causesThough overprescribing opioids may have contributed to the current epidemic, many addiction experts believe that the root causes remain poverty, incarceration, drug and health policies, stigma toward people who use drugs, and a lack of access to drug treatment.Yet much of what has been done to end the opioid epidemic has focused mainly on [reducing the number of prescription painkillers] and improving drug monitoring programs to identify newly filled prescriptions, which are not the real solutions to the growing opioid epidemic. In my view, there has been no clear policy action or plan to address the major root causes of the problem and improve access to drug treatment. President Donald Trump‘s plan to address the opioid epidemic emphasizes punishment, reduction of supply, and law enforcement strategies with no potential to produce an important change in the crisis.Here are my six recommendations to address the opioid epidemic.Increase Medicaid coverage for drug treatment in all statesThe number of states providing benefits for addiction treatment grew with the creation of Affordable Care Act in 2010 and the expansion of Medicaid benefits – but only for states that opted to expand. Now, 32 states and the District of Columbia have adopted Medicaid expansion, which provides medical coverage including addiction treatment for most low-income adults.However, an estimated 2.5 million Americans fall into a coverage gap, where they are not eligible for Medicaid because their state did not expand and they make too little to qualify for marketplace subsidies.Integrate drug treatment into primary careMedication-assisted treatment – the practice of treating addiction with medicines – must be made available in primary care settings and integrated with health care services. The majority of the 2.5 million individuals with an opioid use disorder do not receive evidence-based MAT. Few states have integrated this treatment.The Affordable Care Act is designed to promote the improved integration of substance use in health care services in a more efficient and cost-effective way. There is extensive scientific evidence supporting integration into primary care.Some of the major barriers include state and federal regulations on credentialing and provision of medication-assisted treatment, such as strict rules on how and who can prescribe buprenorphine in primary care settings; shortage of physicians with training to treat substance use disorders; and clinic costs to meet the demands of staff training.Reduce stigma of health care providers toward drug usersWhile health care providers understand addiction is a disease, research shows they commonly view addiction as a moral failure. In fact, studies show that negative attitudes by health professionals toward patients with substance use disorders are common. They are a major reason individuals do not seek, receive or complete addiction treatment or access harm reduction services such as syringe access programs.Increase and customize programs that reduce harmI believe harm reduction – access to services aiming to reduce harm from the addiction rather than just treating it – is critical. Syringe exchange programs allow people with addiction trade in used syringes for new ones, reducing exposure to HIV, hepatitis C or other diseases that occur frequently in those with addiction. Supervised injection facilities would provide a safe place for drug users to inject illicit substances with medical staff nearby.Address neglected populations within the criminal justice systemThose addicted to opioids in prison and jails are often left untreated. Medication-assisted treatment, such as the use of methadone, buprenorphine and naltrexone should be provided to all inmates. Upon release, individuals should receive naloxone to use for themselves or others. To avoid relapse, access to addiction treatment and other care is imperative.The anti-overdose drug naloxone saves hundreds of lives a year. PureRadiancePhoto/Shutterstock.comMake naloxone available to allI have seen countless research participant lives saved by relatives, friends and partners who received naloxone. Recent evidence shows states that actively promoted naloxone experienced 9 to 11 percent reductions in opioid-related deaths. States need strategies to make naloxone available and affordable to everyone, not just first responders. Medicaid should also reimburse naloxone prescriptions for home settings.Even after 30 years, drug use remains stigmatized and individuals are left untreated. Understanding stories like Jennifer’s and John’s help destigmatize drug use and convey the need to address addiction in primary health care settings and link individuals to treatment in their communities. These six points are certainly important; however, I believe there will be resistance from the public because of what their perception of addiction, and addicts, truly is. Therefore, public awareness is vital. Getting information out there is crucial. This is starting to happen because family members of the wealthy and well-known are falling into the grip of addiction, however, it isn’t being disseminated quickly enough. Pharma needs to take greater responsibility; they and physicians need to play a much more important role regarding this huge issue. Is it asking too much that the pharmacological companies hold seminars in each and every state and that physicians be required to attend in order to better understand what the risks are for the medications they prescribe? Sending “flyers” out to the physicians is a mere band-aid. Harm reduction is good, and we can talk about one treatment model versus another, but the money needed will soon become less and less available. Public awareness must become more of a priority if real progress is to take place. And, folks, personal responsibility must be included. There has been little said regarding this aspect of addiction and it’s time for it to be included in the discussion. You have entered an incorrect email address! Please enter your email address here Please enter your comment! Gov. DeSantis says new moment-of-silence law in public schools protects religious freedom LEAVE A REPLY Cancel reply While these may be good ideas, you left out upstream prevention and the Portuguese model. One case history mentioned trauma from childhood sexual abuse. The National Intimate Partner and Sexual Violence Survey shows that sexual violence impacts many children and young adults. It shows that long term consequences are normal and by implication might lead to opiod use. Can you say more and why you did not include this?The Portguese model is being proposed to the Canadian government by the caucus of the members of parliament! If the Trudeau government get a majority in the next election in 2019, I would predict significant expansion in mental health and housing services as well as the Portuguese model. Can you say more and why you did not include this?last_img read more

Supreme Court Seeks Centre’s Response On Plea Alleging No Approval For Remdesivir and Favipiravir To Be Used To Treat COVID-19

first_imgTop StoriesSupreme Court Seeks Centre’s Response On Plea Alleging No Approval For Remdesivir and Favipiravir To Be Used To Treat COVID-19 Sanya Talwar29 Oct 2020 8:29 AMShare This – xThe Supreme Court on Thursday issued notice to the Union Government in a plea alleging that two medicines Remdesivir and Favipiravir are being used for the treatment of COVID-19 without approval. A bench of Chief Justice SA Bobde, Justices AS Bopanna & V. Ramasubramaniun said that the issue needs to be brought to the attention of the Indian Government and issued notice to the Centre.The…Your free access to Live Law has expiredTo read the article, get a premium account.Your Subscription Supports Independent JournalismSubscription starts from ₹ 599+GST (For 6 Months)View PlansPremium account gives you:Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.Subscribe NowAlready a subscriber?LoginThe Supreme Court on Thursday issued notice to the Union Government in a plea alleging that two medicines Remdesivir and Favipiravir are being used for the treatment of COVID-19 without approval. A bench of Chief Justice SA Bobde, Justices AS Bopanna & V. Ramasubramaniun said that the issue needs to be brought to the attention of the Indian Government and issued notice to the Centre.The plea by Advocate ML Sharma alleges that the companies have created media hype around their medicines & exploited citizen’s fears. The plea sought for the prosecution of ten pharmaceutical companies who were allegedly marketing these drugs for COVID-19 treatment. The Supreme Court has however issued notice only to the Central Government.Today, when the matter came up for hearing, Sharma told the Court that he had also annexed a report of the World Health Organisation (WHO) showing that several hundred trials have proven ineffectiveness or little effect of Remdisivir and Favipiravir on COVID19 patients. “This has been corroborated by Chinese, Americans,” he said.The plea states that it is “challenging manufacturing and supply of Drugs without license & seeking writ direction to C.B.I. for investigation and to file their report before this Hon’ble court for further direction to prosecute all involved accused persons u/s s.18 & 27A of the Drugs and Cosmetics Act, 1940 and S.420 &120-B of IPC couple with further directions for recovery of compensation to pay to all Covid patients including doctors in the interest of justice.”The plea has alleeed that Cipla Ltd., Dr. Reddy’s Laboratories, Hetero Labs Ltd., 6. Zydus Cadila Healthcare Ltd., Mylan, Jubilant Life Sciences Limited, Syngene International Ltd, Biocon Company, Jenburkt Pharmaceuticals Limited & Sun Pharma are Indian pharmaceutical company who have signed partnership agreement with foreign companies i.e. Gilead Science Inc USA and Fujifilm Japan, to manufacture and sell the drug, Remdesivir & Avagin (Favipiravir) in India. “Without having a licence, they are manufacturing and selling impugned drugs as a Medicine for corona in India,” says Sharma in his Plea.That impugned two drugs, Remdesivir of Gilead Science Inc USA and & Avagin (Favipiravir) of Fujifilm Toyama Chemical, japan are not admitted and certified as a medicine for Covid-19 till date by any country. It’s under trial and no country, including India, have issued licence to manufacture and sale it in the country. It is adulterated drug. However, is allowed under strict terms by FDA-USA to test in emergencies under strict control of the doctors’ subject to report of each testing report to FDA regularly.- Plea in SCIn this backdrop, Sharma has contended that the issue is a serious injury to the life and liberty to the citizens of India and is in violation of Article 21 as well as the Drugs and Cosmetics Act, 1940.Sharma has further stated that “Indians cannot be used as a human animal for Lab Testing object by companies for their uncertified drugs”.”……more than 300 government doctors died despite using impugned Avagin (Favipiravir) & Remdesivir in hand supplied by the respondent’s companies therefore respondent companies and their directors are liable to be prosecuted u/s 27A of the Drug Acts. The death is not only due to covid-19 but happened also due to reliability and use of impugned drugs of Corona being convinced by the respondent companies via media hype. It’s a subject matter of the C.B.I. investigation to identifies supplier responsible for inducement to use impugned drug which were not effective and in result led to death,” the plea states.Additionally, the petition has also sought issuance of directions to recover proper compensations from these companies to pay to the all exploited citizen of India, including all doctors (private and government) who died despite using impugned drugs supplied inducing it as a medicine for corona by the respondent companies .In furtherance of his prayers, the petitioner has sought issuance of directions to the Centre for providing facilities, scheme and compensation from the Government to all the families of doctors immediately.Next Storylast_img read more